Reactivation of hepatitis b virus during treatment of hepatitis C genotype 3 with daclatasvir and sofosbuvir in a patient with dual infection of hepatitis B and hepatitis C virus

Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.